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Background: Accumulating evidence indicates that iron oxide nanoparticles modulate immune 
responses, and induce oxidative stress in macrophages. It was recently reported that iron oxide 
nanoparticles attenuated antigen-specific immunity in vivo, though the underlying mechanism 
remains elusive. The present study investigates the direct effect of iron oxide nanoparticles on 
antigen-specific cytokine expression by T cells, and potential underlying mechanisms.
Methods: Ovalbumin-primed splenocytes were exposed to iron oxide nanoparticles, followed 
by restimulation with ovalbumin. Cell viability, cytokine production, and cellular levels of 
glutathione and reactive oxygen species were measured.
Results: The splenocyte viability and the production of interleukin-2 and interleukin-4 were 
unaffected, whereas interferon-γ production was markedly attenuated by iron oxide nanopar-
ticles (10–100 µg iron/mL) in a concentration-dependent manner. Iron oxide nanoparticles also 
transiently diminished the intracellular level of glutathione, with a peak response at 6 hours 
posttreatment. The effects of iron oxide nanoparticles on interferon-γ and glutathione were 
attenuated by the presence of N-acetyl-L-cysteine, a precursor of glutathione. However, iron 
oxide nanoparticles did not influence the generation of reactive oxygen species.
Conclusion: Iron oxide nanoparticles induced a differential effect on antigen-specific cytokine 
expression by T cells, in which the T helper 1 cytokine IFN-γ was sensitive, whereas the 
T helper 2 cytokine interleukin-4 was refractory. In addition, the suppressive effect of iron oxide 
  nanoparticles on interferon-γ was closely associated with the diminishment of glutathione.
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Introduction
Nanomaterials have been increasingly applied in numerous fields, including 
  nanomedicine. Among various biomedical nanoparticles, superparamagnetic iron 
oxide   nanoparticles have been used in clinical settings as a contrasting agent to 
enhance magnetic resonance imaging.1,2 In addition, iron oxide particles have shown 
promising potential for cell labeling, cancer therapy, and drug delivery.2–4 It has been 
well-documented that iron oxide nanoparticles administered systemically are rapidly 
engulfed by the reticuloendothelial system, with the liver and spleen being the main 
distribution sites for the particles.5–7 Because phagocytes are one of the major cell 
groups exposed to iron oxide nanoparticles, the potential effect of nanoparticles on 
the functionality of immune cells and host immune competency is a concern, and is 
under intensive investigation.
Accumulating evidence indicates that exposure to iron oxide nanoparticles causes 
apoptosis and alters the functionality of macrophages.8–12 Primary macrophages exposed 
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to iron oxide nanoparticles in culture showed a marked 
increase of apoptosis, accompanied by elevated generation of 
reactive oxygen species (ROS).10 Similarly, exposure of the 
murine macrophage cell line J774 to iron oxide nanoparticles 
resulted in an increased production of intracellular ROS, 
with subsequent cell injury and apoptosis.13 Murine studies 
further showed that a single intratracheal instillation of iron 
oxide nanoparticles had proinflammatory and prooxidative 
effects, as evidenced by a marked infiltration of inflammatory 
cells into the lungs and a diminished level of intracellular 
glutathione in bronchoalveolar lavage cells.12 Collectively, 
these results have demonstrated the immunomodulatory and 
cytotoxic effects of iron oxide nanoparticles on macrophages, 
possibly through oxidative stress-related mechanisms.
In addition to macrophages, other immune cells are also 
sensitive to iron oxide nanoparticles. For example, the 
  function of dendritic cells to process antigens and stimulate 
T cells were suppressed by iron oxide nanoparticles.14 Several 
animal studies have reported that T cells are another target 
in the immune system sensitive to iron oxide nanoparticles. 
Both oral and intravenous administrations of iron oxide 
nanoparticles to normal nonsensitized mice altered T cell 
cellularity.15,16 The serum levels of interleukin (IL)-2, IL-10, 
and interferon (IFN)-γ were elevated in mice intravenously 
treated with iron oxide nanoparticles.16 Furthermore, it was 
recently reported that a single systemic administration of 
iron oxide nanoparticles attenuated the serum production of 
antigen-specific immunoglobulin (IgG)1 and IgG2a and the 
expression of IL-4 and IFN-γ by splenocytes, in ovalbumin 
(OVA)-sensitized mice.17 These results demonstrate that 
exposure to iron oxide nanoparticles influences T cell func-
tionality in both nonsensitized and antigen-sensitized mice. 
However, the underlying mechanisms remain elusive, and 
whether iron oxide nanoparticles produce a direct effect on 
T cells remains unclear.
The present study investigated the direct effect of iron 
oxide nanoparticles on antigen-specific T cell reactivity by 
using OVA-primed splenocytes in culture. Furthermore, 
in light of the available evidence showing the cytotoxic 
and prooxidative effects of iron oxide nanoparticles on 
  macrophages, the potential role of oxidative stress and 
  cellular glutathione in iron oxide nanoparticle-mediated 
effects on T cells was also addressed.
Materials and methods
Reagents and chemicals
All reagents were obtained from Sigma-Aldrich Corporation 
(St Louis, MO), unless otherwise stated. Reagents and 
antibodies for enzyme-linked immunosorbent assay were 
purchased from BD Biosciences – Pharmingen (Becton, 
Dickinson and Company, San Diego, CA). Fetal bovine 
serum and cell culture supplies were purchased from Thermo 
Fisher Scientific (Logan, UT). A commercial preparation of 
carboxydextran-coated iron oxide nanoparticles containing 
28 mg iron (Fe)/mL, namely ferucarbotran (Resovist®; 
Schering AG, Berlin-Wedding, Germany), was used in the 
present study. According to its package insert, the hydrody-
namic diameters of the coated particles range from 45 nm to 
60 nm. Results from confirmatory experiments revealed that 
Resovist exhibited a monodisperse population of particles 
with an average diameter to be 58.7 nm, using a particle 
size analyzer (Zetasizer Nano S, Malvern Instruments Ltd, 
Malvern, Worcestershire, United Kingdom). The crystal-
line core of ferucarbotran is composed of magnetite and 
maghemite.5
Animals
Male BALB/c mice (5–6 weeks old) were purchased from 
BioLasco Taiwan Co, Ltd (Taipei, Taiwan). On arrival, the 
mice were randomly transferred to plastic cages containing 
aspen bedding, with five mice per cage, and quarantined for 
at least 1 week. The mice were housed in an environment in 
which temperature (22°C ± 2°C), humidity (50% ± 20%), 
and light (12-hour light/dark cycle) were controlled. Food 
and water were supplied ad libitum. All animal experiments 
were approved by the Institutional Animal Care and Use 
Committee of the National Taiwan University.
OVA-primed splenocytes
BALB/c mice were sensitized twice with OVA by intraperi-
toneal injection on days 0 and 14. On these days, each mouse 
was injected with 250 µL sensitization solution, containing 
20 µg OVA and 2 mg alum (as adjuvant) in saline. On day 
15, the mice were euthanized and their spleens were harvested 
aseptically and made into single cell suspensions as described 
previously.17 The obtained OVA-primed splenocytes were 
cultured in Roswell Park Memorial Institute 1640 medium 
supplemented with 100 U/mL penicillin, 100 µg/mL strepto-
mycin, and 5% heat-inactivated fetal bovine serum. In all cases, 
splenocytes were cultured at 37°C in 5% carbon dioxide.
Measurement of splenocyte viability
The viability of splenocytes was determined by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide 
(MTT) assay described previously.18 In brief,   splenocytes 
(5 × 106 cells/mL) were seeded into 96-well plates (100 µL/well) 
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and treated with iron oxide nanoparticles (1–100 µg Fe/mL) 
and/or vehicle (VH; Roswell Park   Memorial Institute medium). 
Each iron oxide treatment was administered in quadruplicate. 
The iron oxide concentration range used corresponded with 
0.11–11 times the estimated plasma concentration (9 µg/
mL) at a dose of 447 µg Fe/kg.19 For the next 44 hours, the 
cells were either left unstimulated or were stimulated with 
OVA (100 µg/mL). An MTT stock solution (5 mg/mL in 
phosphate buffered saline) was then added to each well (10 µL/
well) and incubated for 4 hours. The formed formazan was 
dissolved with 0.1 N   acid-  isopropanol (100 µL/well), and 
optical density was measured at 570 nm, and at 630 nm as a 
background reference, using a microplate reader (SpectraMax 
M5, Molecular Devices, Sunnyvale, CA).
Cytokine measurement
Splenocytes (5 × 106 cells/mL) were cultured in 48-well 
plates (250 µL/well) and treated with iron oxide nanoparticles 
(1–100 µg Fe/mL) and/or VH, followed by stimulation with 
OVA (100 µg/mL) for 48 hours. Each iron oxide treatment 
was administered in triplicate. The supernatants were har-
vested and quantified for IL-2, IL-4, and IFN-γ by enzyme-
linked immunosorbent assay. The level of cytokines in the 
VH group was designated as 100%, and the percentage of 
inhibition induced by treatment of iron oxide nanoparticles 
was calculated according to the following formula:
% of inhibition  
  = ([Cytokine levelVH - Cytokine levelIron oxide nanoparticles] 
    /Cytokine levelVH) × 100%
Flow cytometric analysis of intracellular 
glutathione
Splenocytes (5 × 106 cells/mL) were seeded into 48-well 
plates (250 µL/well) and treated with iron oxide nanopar-
ticles (1–100 µg Fe/mL) and/or VH, followed by stimulation 
with OVA (100 µg/mL) for 6 hours. Each iron oxide treat-
ment was administered in triplicate. The cells were incubated 
with monochlorobimane (20 µM) for 20 minutes. The single 
cell fluorescence for each sample was measured at emission 
of 525 nm and excitation of 355 nm using a flow cytometer 
(BD LSRFortessa cell analyzer; BD Biosciences – Immu-
nocytometry Systems, Becton, Dickinson and Company, 
San Jose, CA). The data were analyzed using the software 
Flowjo 5.7 (Tree Star, Inc, Ashland, OR).
ROS measurement
Splenocytes (5 × 106 cells/mL) were preincubated with 20 µM 
dichlorofluorescin diacetate for 30 minutes at 37°C. The 
splenocytes preloaded with dichlorofluorescin diacetate were 
cultured in a 96-well opaque plate (100 µL/well) and treated 
with iron oxide nanoparticles (1–100 µg Fe/mL) and/or VH, 
followed by stimulation with OVA (100 µg/mL) for 6 hours. 
Each iron oxide treatment was administered in triplicate. Each 
iron oxide treatment was administered in triplicate. To mea-
sure the levels of intracellular ROS, the cells were lysed with 
dimethyl sulfoxide (10 µL/well) and measured at excitation of 
488 nm and emission of 525 nm using a microplate reader.
Statistical analysis
The mean ± standard error was determined for each treat-
ment group in the individual experiments. Normality and 
homoscedasticity of data were tested by the Shapiro–Wilk 
test. Homogeneous data were then evaluated by a parametric 
analysis of variance, and Dunnett’s two-tailed t-test was used 
to compare the results for the treatment groups with those of 
the control group. For experiments with N-acetyl-L-cysteine 
pretreatment (NAC), the data were evaluated by two-way 
analysis of variance and Duncan’s multiple range test, using 
the Statistical Analysis System (v 9.1; SAS Institute Inc, 
Cary, NC). Statistical significance was defined as a P value 
of less than 0.05.
Results
No effect of iron oxide nanoparticles  
on splenocyte viability
Using an MTT assay, it was examined whether iron oxide 
nanoparticles caused cytotoxicity. OVA-primed splenocytes 
were exposed to iron oxide nanoparticles (1–100 µg Fe/mL) 
and/or VH, followed by stimulation with OVA (100 µg/mL). 
For nonstimulated controls, the splenocytes were exposed to 
iron oxide nanoparticles but did not receive OVA stimulation. 
The results showed that regardless of whether cells were or 
were not stimulated by OVA, the iron oxide nanoparticles did 
not influence the viability of splenocytes (Figure 1).
Differential effects of iron oxide 
nanoparticles on the expression  
of antigen-specific cytokines
The effects of iron oxide nanoparticles on the expression of 
three cytokines predominantly expressed by T cells, namely 
IL-2, IFN-γ, and IL-4, were examined. The production of 
cytokines by unstimulated splenocytes was very low, whereas 
OVA stimulation strongly induced the expression of the 
three cytokines (Figure 2A–C, naïve versus VH). The pres-
ence of iron oxide nanoparticles (10–100 µg Fe/mL) did not 
  influence the production of IL-2 and IL-4, whereas IFN-γ was 
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Figure  1  No  effect  of  iron  oxide  nanoparticles  on  viability  of  splenocytes. 
Splenocytes (5 × 106 cells/mL) were treated with iron oxide nanoparticles (1–100 µg 
iron [Fe]/mL) and/or vehicle (VH; Roswell Park Memorial Institute medium) and 
then either left unstimulated or stimulated with ovalbumin (OVA; 100 µg/mL) for 
44 hours. The viability of splenocytes was determined by 3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyl-tetrazolium bromide assay. 
Notes: Data are expressed as the mean ± standard error of quadruplicate cultures. 
Results are representative of three independent experiments. 
Abbreviation: OD, optical density.
markedly suppressed in a concentration-dependent manner 
(Figure 2A–C).
Previous reports have indicated that iron oxide 
nanoparticles cause oxidative stress in macrophages.10,13 
Therefore the potential role of oxidative stress as a possible 
mechanism for the effect of iron oxide nanoparticles on IFN-γ 
was investigated. For this purpose we used NAC, a thiol 
antioxidant as well as a precursor of glutathione. The presence 
of NAC (1 mM)   markedly attenuated iron oxide nanoparticle-
mediated   inhibition of IFN-γ production (Figure 2D). In the 
absence of NAC, the magnitude of inhibition induced by 10, 
50, and 100 µg Fe/mL of iron oxide nanoparticles on IFN-γ 
was 45.1%, 86.1%, and 95.4%, respectively (Figure 2C). 
In the presence of NAC, these percentages were attenuated 
to 18.3%, 39.8%, and 87.8%, respectively (Figure 2D).
Attenuation of iron oxide nanoparticle-
mediated inhibition of IFN-γ by thiol,  
but not nonthiol, antioxidants
In addition to NAC, several thiol and nonthiol antioxidants 
were employed to further address the involvement of oxida-
tive stress. Both NAC and exogenous glutathione (1–4 mM 
of each) were found to significantly attenuate iron oxide 
nanoparticle (50 µg Fe/mL)-mediated suppression of IFN-γ in 
a concentration-dependent manner (Table 1). In contrast, the 
nonthiol antioxidants pyruvate (1–4 mM), dimethylthiourea 
(4 mM), and tiron (100 µM) did not reverse the effects of 
iron oxide nanoparticles (Table 1).
Diminishment of intracellular glutathione 
by iron oxide nanoparticles
Based on the results showing the effectiveness of thiol 
antioxidants, the influence of iron oxide nanoparticles 
on intracellular levels of glutathione in splenocytes was 
examined. Exposure of splenocytes to iron oxide nanopar-
ticles (50 µg Fe/mL) markedly decreased the monochlo-
robimane fluorescence with a peak response at 6 hours 
postexposure, indicating a diminished level of intracellular 
glutathione (Figure 3A). The effect of iron oxide nanopar-
ticles (1–100 µg Fe/mL) on glutathione diminishment was 
concentration-dependent, and was significantly reversed by 
the presence of NAC (1 mM) (Figure 3B). In addition to 
glutathione, the level of intracellular ROS was also measured 
in splenocytes exposed to iron oxide nanoparticles. At the 
time point (6 hours) showing peak glutathione diminish-
ment, no significant changes in ROS levels were detected 
in splenocytes exposed to iron oxide nanoparticles up to 
100 µg Fe/mL (Figure 4).
Discussion
Although iron oxide nanoparticles have been shown to 
affect the functionality and apoptosis of macrophages,8–12 
evidence pertaining to their effects on other immune cells 
is limited. It was previously reported that systemic expo-
sure of OVA-sensitized mice to iron oxide nanoparticles 
attenuated the production of antigen-specific antibodies 
and T cell cytokines.17 In the present study, it was further 
investigated whether iron oxide nanoparticles induced a 
direct effect on T cells in culture. The data demonstrated that 
direct exposure of OVA-primed splenocytes to iron oxide 
nanoparticles in culture resulted in a marked suppression 
of IFN-γ expression and a decrease in intracellular glutathi-
one levels. These results provide evidence that iron oxide 
nanoparticles produce a direct effect on antigen-specific 
T cell responses.
In contrast to the suppressive effect on IFN-γ, iron oxide 
nanoparticles did not influence OVA-induced production of 
IL-2 and IL-4. Previous research has established that IFN-γ 
and IL-4 are signature cytokines expressed by T helper (Th)1 
and Th2 cells, respectively.20 The current findings suggested 
a differential sensitivity between Th1 and Th2 cells, with 
Th1 cells being a more sensitive target to the nanoparticles. 
This notion is in line with a recent report showing that 
antigen-specific IgG2a and IFN-γ were slightly more sensi-
tive than IgG1 and IL-4 regarding suppression by iron oxide 
nanoparticles in vivo.17 On the basis of these results, it was 
speculated that exposure to iron oxide nanoparticles may 
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switch the Th1/Th2 immunobalance toward Th2-dominant 
immunity in response to antigen stimulation. The potential 
effect of iron oxide nanoparticles on immune responses medi-
ated by Th1 and Th2 cells warrants further investigations 
using appropriate models.
These data on antigen-specific T cell responses contradict 
the findings of a previous study, which reported that a single 
intravenous administration of iron oxide nanoparticles to 
  normal nonsensitized mice elevated the serum level of 
IFN-γ.15 Although the mechanism responsible for these 
contradictory results remains to be elucidated, apparently a 
crucial factor dictating the effect of iron oxide nanoparticles on 
IFN-γ production may be the absence or presence of antigen 
sensitization. In the authors’ studies, IFN-γ production is 
antigen-specific. In contrast, the elevated IFN-γ in nonsensitized 
mice has been interpreted as a possible proinflammatory status 
induced by iron oxide nanoparticles.15
Iron oxide nanoparticles reportedly cause cytotoxicity 
in macrophages.13 In the present study, the cell viability 
of splenocytes was monitored using an MTT assay, which 
showed comparable viability between nanoparticle-treated 
and VH-treated groups. Hence, the effect of iron oxide 
nanoparticles on cytokine expression evidently should not 
be attributed to a general cytotoxic mechanism.
The authors’ mechanistic studies revealed that both the 
IFN-γ suppression and the glutathione diminishment induced 
by iron oxide nanoparticles were significantly reversed by 
NAC, a glutathione precursor. Glutathione plays a critical 
role in maintaining the cellular homeostasis of redox balance. 
Both NAC and glutathione can function as ROS scavengers.21 
Notably, iron oxide nanoparticles have been reported to cause 
oxidative stress in several cells, including those of immune 
origin.10,13 It was therefore also evaluated whether ROS were 
induced in the present study’s experimental   conditions. 
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Figure 2 Differential effects of iron oxide nanoparticles on the production of antigen-specific interleukin (IL)-2, IL-4, and interferon (IFN)-γ by splenocytes. (A−C) Splenocytes 
(5 × 106 cells/mL) were either left untreated (naïve; NA) or treated with iron oxide nanoparticles (1-100 µg iron [Fe]/mL) and/or vehicle (VH) followed by stimulation 
with ovalbumin (100 µg/mL) for 48 hours. (D) Splenocytes were pretreated with N-acetyl-L-cysteine (NAC; 1 mM) prior to the treatment of iron oxide nanoparticles and 
ovalbumin stimulation described above. The levels of (A) IL-2, (B) IL-4, and (C and D) IFN-γ in the supernatants were measured by enzyme-linked immunosorbent assay. 
Notes: Data are expressed as the mean ± standard error of triplicate cultures. The level of cytokines in the VH group was designated as 100%, and the percentage of 
inhibition induced by iron oxide nanoparticles (10-100 µg Fe/mL) was calculated against this standard (as indicated in parentheses). *P , 0.05, comparison with VH group. 
Results are representative of three independent experiments. 
Abbreviation: ND, no data.
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However, all three nonthiol antioxidants which were used, 
namely pyruvate, dimethylthiourea, and tiron, failed to coun-
teract the effects of iron oxide nanoparticles. Moreover, iron 
oxide nanoparticles did not alter the intracellular level of 
ROS in splenocytes restimulated with OVA, as measured by 
dichlorofluorescin fluorescence. Overall, these results provided 
evidence to differentiate the respective contributions of gluta-
thione and ROS in iron oxide nanoparticle-mediated effects, 
with glutathione rather than ROS playing a central role.
Similar findings were reported from a previous study on 
human cardiac endothelium, in which ROS was not found 
to play a positive mediating role. In that study, iron oxide 
nanoparticles were found not to induce cytotoxicity and ROS 
production in human cardiac endothelial cells.22 Another 
recent report showed that titanium dioxide nanoparticles 
induced ROS production in both Escherichia coli MG1655 
and Cupriavididus metallidurans CH34, but caused cytotox-
icity only in E. coli MG1655.23 Overall, these results suggest 
that the induction of ROS production and the contribution of 
ROS in metal oxide nanoparticle-mediated cytotoxic effects 
vary across different cells.
By contrast, previous research has documented that 
glutathione plays a pivotal role in various T cell functions, 
such as the regulation of cytokine expression.24,25 Glutathione 
is considered the hallmark redox buffer in living cellular 
systems. Depletion of cellular glutathione in mice fed with 
a liquid control diet containing 30% ethanol-derived calories 
was found to downregulate the production of antigen-
specific IFN-γ when also upregulating IL-4 production, 
but did not affect the level of IL-2.24 In addition, depletion 
of intracellular glutathione by buthionine sulfoximine 
differentially   influenced the functionality of Th1/Th2 cell 
clones.   Specifically, IL-2-induced DNA synthesis was 
attenuated in the IFN-γ producing Th cell clone 29, whereas 
DNA synthesis in the IL-4 producing Th cell clone D10.
G4.1.HD was not affected.26 The current findings were 
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Figure 3 Diminishment of intracellular glutathione in the presence of iron oxide 
nanoparticles  in  splenocytes.  (A)  Splenocytes  (5  ×  106  cells/mL)  were  treated 
with iron oxide nanoparticles (50 µg iron [Fe]/mL) and/or vehicle (VH) followed 
by stimulation with ovalbumin (100 µg/mL) for 1–12 hours. (B) Splenocytes were 
treated with iron oxide nanoparticles (1–100 µg Fe/mL) and/or VH, followed by 
stimulation with ovalbumin (100 µg/mL) for 6 hours in the absence or presence 
of N-acetyl-L-cysteine (NAC; 1 mM). The levels of intracellular glutathione were 
measured as monochlorobimane (MCB) fluorescence by flow cytometry. 
Notes: Data are expressed as the mean ± standard error of triplicate cultures. 
*P , 0.05, comparison with matched control group without nanoparticle treatment. 
#P , 0.05, comparison with matched nonNAC group. Results are representative of 
three independent experiments.
Table 1 Effects of thiol and nonthiol antioxidants on iron oxide 
nanoparticle-mediated suppression of interferon-γ production by 
splenocytes
Antioxidants Iron oxide nanoparticle-mediated 
inhibition of interferon-γ 
production (%)a
Control 85.8 ± 2.6
N-acetyl-L-cysteine (mM)
 1 39.3 ± 8.9*
 2 35.6 ± 6.4*
 4 27.9 ± 4.8*
Glutathione (mM)
 1 41.5 ± 6.2*
 2 36.1 ± 8.5*
 4 29.7 ± 4.1*
Pyruvate (mM)
 1 82.3 ± 6.9
 4 84.3 ± 3.1
Dimethylthiourea (mM)
 4 89.7 ± 1.0
Tiron (mM)
  0.1 86.6 ± 1.2
Notes: aSplenocytes (5 × 106 cells/mL) were pretreated with iron oxide nanoparticles 
(50  µg  iron/mL)  in  the  absence  (control)  or  presence  of  N-acetyl-L-cysteine, 
glutathione,  pyruvate,  dimethylthiourea  or  tiron,  followed  by  stimulation  with 
ovalbumin (100 µg/mL) for 48 hours. The levels of interferon-γ in the supernatants 
were measured by enzyme-linked immunosorbent assay. The percentage of inhibition 
induced by iron oxide nanoparticles was calculated as described in Materials and 
methods. Data are expressed as the mean ± standard error of six samples pooled 
from two experiments; *P , 0.001 compared to the control.
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congruent with these reports and showed that iron oxide 
nanoparticles diminished the intracellular glutathione and 
suppressed the production of IFN-γ, whereas IL-2 and IL-4 
were unaffected.
Conclusion
The present study demonstrated that direct exposure of 
antigen-primed splenocytes to iron oxide nanoparticles 
resulted in a marked suppression of the expression of 
antigen-specific IFN-γ, accompanied by a decrease in 
intracellular glutathione. Both the IFN-γ suppression 
and glutathione diminishment were reversed by the thiol 
antioxidant NAC, but not by nonthiol antioxidants. These 
findings constitute the first reported evidence of the critical 
role played by glutathione in the immunosuppressive effect 
of iron oxide nanoparticles on T cells.   Accumulating evi-
dence suggests that iron oxide nanoparticles may drive 
macrophages toward   proinflammatory responses and 
affect T cell reactivity.8–10,15–17 Thus, it would be prudent 
to further investigate the immunopharmacology and 
immunotoxicology of these nanoparticles, and to consider 
their possible biomedical application in vivo.
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Figure 4 No effect of iron oxide nanoparticles on the intracellular levels of reactive 
oxygen species. Splenocytes (5 × 106 cells/mL) preloaded with dichlorofluorescin 
(DCF) diacetate (20 µM) were treated with iron oxide nanoparticles (1–100 µg iron 
[Fe]/mL) and/or vehicle (VH), followed by stimulation with ovalbumin (100 µg/mL) 
for 6 hours. The levels of intracellular reactive oxygen species were measured as 
DCF fluorescence using a microplate reader. 
Notes: Data are expressed as the mean ± standard error of triplicate cultures. 
Results are representative of three independent experiments.
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